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DFS = disease-free survival; ELISA = enzyme-linked immunosorbent assay; ER = estrogen receptor; HER = human epidermal growth factor recep-
tor; IHC = immunohistochemistry; PAI = plasminogen activator inhibitor; PCR = polymerase chain reaction; PR = progesterone receptor; RT =
reverse transcription; uPA = urokinase-type plasminogen activator.
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Introduction
Breast cancer is the most common malignancy in women,
and it is highly curable if diagnosed at an early stage.
Traditional prognostic factors include the axillary lymph
node status, the tumor size, and the nuclear grade and
histologic grade. Interest in novel prognostic markers is
based on the fact that a significant number of patients
with early-stage breast cancer harbor microscopic meta-
stasis at the time of diagnosis. It is now well established
that adjuvant systemic therapy improves survival in
patients with early-stage breast cancer [1,2]. Treatment
options for early-stage breast cancer include chemo-
therapy (e.g. anthracyclines, taxanes) and hormone therapy
(e.g. tamoxifen, aromatase inhibitors). The use of trastuzu-
mab is under investigation in the adjuvant setting for
patients with human epidermal growth factor receptor
(HER) 2 overexpressing breast cancer.
Systemic therapies are potentially toxic, however, and
identifying the individual patients who are at high risk and
likely to benefit remains a major challenge. For example,
the risk of recurrence for a patient with negative axillary
lymph nodes and a tumor measuring 1–2 cm is approxi-
mately 20–30%. Most patients in this group are currently
offered adjuvant systemic therapy, although up to 70% of
patients would not need it because they are already cured
of their disease. Unfortunately, the histologic information is
clearly not sufficient to accurately assess individual risk
and to possibly avoid adjuvant systemic therapy. A large
number of molecular markers have been studied to
determine their ability to predict prognosis or response to
therapy, or both (Table 1). Prognostic factors correlate
with survival independent of systemic therapy, and are
used to select patients at risk. Predictive factors correlate
response to therapy independent of prognosis, and have a
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Abstract
A multitude of molecules involved in breast cancer biology have been studied as potential prognostic
markers. In the present review we discuss the role of established molecular markers, as well as
potential applications of emerging new technologies. Those molecules used routinely to make
treatment decisions in patients with early-stage breast cancer include markers of proliferation (e.g. Ki-
67), hormone receptors, and the human epidermal growth factor receptor 2. Tumor markers shown to
have prognostic value but not used routinely include cyclin D1 and cyclin E, urokinase-like plasminogen
activator/plasminogen activator inhibitor, and cathepsin D. The level of evidence for other molecular
markers is lower, in part because most studies were retrospective and not adequately powered,
making their findings unsuitable for choosing treatments for individual patients. Gene microarrays have
been successfuly used to classify breast cancers into subtypes with specific gene expression profiles
and to evaluate prognosis. RT-PCR has also been used to evaluate expression of multiple genes in
archival tissue. Proteomics technologies are in development.
Keywords: biological tumor markers, breast cancer, genomics, prognosis, proteomics110
Breast Cancer Research    Vol 6 No 3 Esteva and Hortobagyi
significant impact in selected patient populations. Some
molecular markers are associated with prognosis, some
are associated with response to therapy, and some are
associated with both.
Although a large number of molecules have been investiga-
ted as potential prognostic and predictive factors, the
National Institute of Health Consensus Development
Conference held in 2000 stressed the need for validation
and appropriate quality control for most of the markers
studied to date [3]. The present article reviews the available
data on established and investigational prognostic
molecular markers in patients with early-stage breast cancer.
Proliferation markers
The tumor proliferation rate is an important prognostic
factor in breast cancer. Several methods have been
developed to estimate the proliferative rate of tumor cells.
The S-phase fraction, as measured by flow cytometry, is a
validated method for measuring tumor proliferation [4].
However, flow cytometry is not commonly used because
of the amount of tissue consumed for the assay.
Alternative methods for measuring tumor proliferation have
been developed, including immunohistochemistry (IHC) to
detect cell cycle-related antigens, that are better suited for
the evaluation of small archival tissue samples.
Ki-67 is a nuclear antigen found in cells in the proliferative
phases of the cell cycle (G1 phase, S phase, G2 phase,
and M phase) but not cells in the resting phase (G0
phase). MIB-1 is a monoclonal antibody that identifies the
Ki-67 protein in paraffin-embedded tissue. A strong
correlation has been noted between the percentage of
cells showing Ki-67 staining and the nuclear grade, age,
and mitotic rate [5,6]. Patients whose tumors overexpress
Ki-67 in more than 50% of the cells are at high risk of
developing recurrent disease [7]. In addition, Ki-67
correlates with other well-characterized proliferation markers,
such as the proliferating cell nuclear antigen [6].
Mitosin, a recently described 350-kDa nuclear phospho-
protein, is expressed in the late G1 phase, S phase, G2
phase, and M phase of the cell cycle, but not in the G0
phase [8]. Clark and colleagues [9] showed that mitosin is
a proliferation marker that correlates with high S-phase
fraction and negative estrogen receptor (ER)/progesterone
receptor (PR) status. Although mitosin was not a predictor
of survival in the study by Clark and colleagues, it was an
independent predictor of recurrence. Additional studies
are necessary to validate these findings.
Estrogen receptors and progesterone receptors
Estrogen mediates its functions through two specific
intracellular receptors, the ERα and the ERβ, which act as
hormone-dependent transcriptional regulators [10,11].
The ER pathway plays a critical role in the patho-
physiology of human breast cancer. Overexpression of
ERα is a well-established prognostic and predictive factor
in breast cancer patients. The prognostic significance of
ERβ is not well defined [12–15]. Overexpression of the
PR serves as a functional assay because it indicates that
the ER pathway is intact, even if the tumor is reported as
ER-negative. When biochemical ligand-binding assays
indicate concentrations of 10 fmol/mg cytosol protein or
more, the tumors are generally considered ER-positive and
PR-positive for clinical purposes.
The ER and PR status can be measured using IHC. The
results of IHC correlate closely with biochemical ligand-
binding assays and with clinical response rates to
endocrine therapy [16]. Because IHC, unlike chemical
assays, does not require the destruction of tissue specimens,
and because it shows the tissue distribution of ER, it has
become the preferred method for determining the ER/PR
status in breast cancer specimens. Quantitative methods
using computer-aided image analysis are being developed
to improve the accuracy of IHC.
The value of ER status as an independent prognostic
variable is diminished by its association with other
established indicators of favorable prognosis. These
include older age, low-grade histology, a favorable nuclear
grade, a low S-phase fraction, a normal complement of
DNA, a low proliferative index, and a low thymidine-
labeling index [17]. In addition, ER-positive patients receive
and benefit from either adjuvant or palliative hormone
therapy so regularly that it is difficult to evaluate the
prognosis apart from the influence of therapy.
In some studies, the higher disease-free survival (DFS)
and overall survival rates of patients with ER-positive
tumors are seen only in the presence of hormone therapy.
Often the favorable effect of ER-positive status as a
Table 1
Well-established and investigational prognostic factors in
breast cancer
Well-established Investigational 
prognostic factor prognostic factor
Ki-67 pS2
Estrogen receptor Mitosin
Progesterone receptor Epidermal growth factor receptor
HER-2 Insulin-like growth factors
Apoptosis-related proteins
Cell cycle molecules
Plasminogen activators and inhibitors
Angiogenesis-related proteins111
discriminant is lost after several years, suggesting that the
influence of treatment is temporary [18,19]. When node-
positive patients not receiving adjuvant hormone therapy
were studied, the 5-year DFS rate was 20% higher for ER-
positive patients compared with that for ER-negative
patients. However, the 5-year DFS rate of the most
favorable subgroup (i.e. patients with one to three positive
nodes and ER-positive tumors) did not exceed 60% [20].
Among node-negative patients, small but statistically
significant differences in DFS and overall survival rates
have been found between ER-positive cases and ER-
negative cases after various periods of follow-up [21]. The
results of a multivariate analysis of prognostic factors by
McGuire and colleagues [22], including the ER status for
more than 3000 patients, showed the ER status to be
more important for prognosis than tumor size in node-
negative cases but not in node-positive cases. In one
study, the ER status was found to be less important for
predicting duration of DFS or overall survival than the
nuclear grade and the number of positive nodes [23].
Allred and colleagues [24] showed that tamoxifen
decreased the risk of local–regional recurrence in patients
with ER-positive ductal carcinoma in situ.
The ER IHC assay is not standardized. Methods of tissue
procurement, preservation, antigen retrieval, and, more
importantly, the definition of positivity vary between
different laboratories.
The prognostic role of ERβ is not well defined. Fuqua and
colleagues [25] evaluated ERβ expression using IHC in
242 breast cancer patients. Their study showed that most
tumors coexpressed both ERα and ERβ. Although ERα
expression was positively correlated with low tumor grade,
with diploidy, and with low S-phase fraction (all biological
parameters of a good prognostic profile), ERβ trended
toward an association only with aneuploidy. No associa-
tion with tumor grade or S-phase fraction was seen for
ERβ. Larger studies are needed to determine the clinical
utility of ERβ expression in breast cancer.
Human epidermal growth factor receptor 2
The most frequently implicated receptors and growth
factors in human breast cancer are members of the
epidermal growth factor receptor subfamily of tyrosine
kinase receptors. In addition to epidermal growth factor
receptor, the type I subfamily includes HER-2, HER-3, and
HER-4 [26,27]. These receptors share a common molecular
architecture; they all possess a large glycosylated
extracellular ligand-binding domain, a single hydrophobic
transmembrane domain, and a cytoplasmic tyrosine kinase
domain.
HER-2 (also known as c-erbB-2 or neu) is a proto-oncogene
that encodes a 185-kDa tyrosine kinase glycoprotein.
Amplification of the HER-2 gene plays an important role in
the pathogenesis of breast cancer [28–30]. The HER-2
protein is overexpressed in 60% of ductal carcinomas in
situ and in 20–30% of infiltrating breast carcinomas
[31,32]. The HER-2 status can be determined in human
tumor samples using IHC or fluorescence in situ
hybridization [32]. Amplification and/or overexpression of
the HER-2 oncogene is associated with a poor DFS rate
in patients with axillary node-positive breast cancer
[32–34].
Allred and colleagues [35] evaluated HER-2 expression
using IHC in 613 patients with node-negative breast
cancer enrolled in the Intergroup Study 0011. In their
study, patients were stratified into low-risk groups
(n = 307) and high-risk groups (n = 306) on the basis of
tumor size and ER status. Low-risk patients were defined
as having small (<3 cm), ER-positive tumors and were
observed without additional treatment after initial surgery.
High-risk patients had either ER-negative tumors or large
(≥3 cm), ER-positive tumors and were randomized to be
observed (n = 146) or to receive adjuvant chemotherapy
(n = 160) after surgery. In Allred and colleagues’ study,
HER-2 was overexpressed in 14.3% of all tumors
combined, and overexpression was higher in invasive
carcinomas associated with an extensive in situ
component (21.5%) than in carcinomas without a
significant noninvasive or in situ histologic component
(11.2%; P < 0.0001). When patients with low-risk lesions
not containing a significant in situ component (n = 179)
were analyzed, HER-2 was a strong prognostic factor.
Patients in this group with HER-2-positive tumors showed
only 40% DFS at 5 years, compared with more than 80%
in patients with HER-2-negative tumors (P < 0.0001).
HER-2 overexpression has been associated with improved
response to doxorubicin-based chemotherapy [36–40].
HER-2 overexpression does not seem to predict response
to taxane-based chemotherapy [41]. The association
between HER-2 overexpression and response to hormonal
therapy is controversial [40,42,43]. Osborne and colleagues
[44] reported an association between the ER coactivator
AIB1 (SRC-3) and tamoxifen resistance, particularly in
patients with HER-2-positive tumors treated with tamoxifen.
One of the main reasons for the clinical utility of the tissue
measurement of HER-2 is for selection of patients with
invasive breast cancer for trastuzumab monoclonal
antibody therapy (Herceptin™; Genentech, San Francisco,
CA, USA). The pivotal clinical trials of trastuzumab were
conducted in patients with metastatic breast cancer
overexpressing HER-2. The HER-2 status was determined
by IHC using two monoclonal antibodies: CB-11 and
4D5. The HER-2 expression was scored as 0, 1+, 2+, and
3+, depending on the number of cells with membrane
staining and on the intensity of the staining. If the tumor
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was 0 or 1+, it was considered HER-2-negative. If the
tumor was 2+ or 3+ it was considered HER-2-positive,
and patients received trastuzumab therapy. Retrospective
studies showed that the response rate for trastuzumab
therapy was higher among patients with an IHC score of
3+ expression compared with patients having a score of
2+. Good correlation was noted between a 3+ score
using IHC and the presence of HER-2 gene amplification
using fluorescence in situ hybrization. Recent data
indicate that fluorescence in situ hybrization may be a
better predictor of response to trastuzumab-based therapy
[45,46]. Trastuzumab is currently approved for treating
patients with metastatic breast cancer. Adjuvant trials are
ongoing to determine the safety and efficacy of
trastuzumab in patients with early-stage breast cancer.
Plasminogen activators and inhibitors
Tumor cell invasion and metastasis is a multifactorial
process that at each step may require the action of
proteolytic enzymes, such as collagenases, cathepsins,
plasmin, or plasminogen activators. Some of these
molecules have been associated with specific prognoses
and are now discussed in more detail.
The urokinase-type plasminogen activator (uPA) is a
serine protease that plays an important role in the invasion
and metastasis process through degradation of the
extracellular matrix. High levels of tissue uPA and its
inhibitors (plasminogen activator inhibitor [PAI]-1, PAI-2)
measured using ELISAs have been correlated with poor
outcome in node-negative breast cancer patients [47–51].
Janicke and colleagues [52] conducted a prospective,
randomized multicenter clinical trial of adjuvant therapy
versus observation for patients with node-negative breast
cancer. In their study, patients whose primary tumors had
low tumor levels of uPA and PAI-1 (low risk) did not
receive adjuvant systemic therapy. Patients with elevated
tumor levels of uPA and/or of PAI-1 (high risk) were
randomized to receive cyclophosphamide, methotrexate,
and 5-fluorouracil adjuvant chemotherapy or to receive no
treatment. The first interim analysis showed an estimated
3-year recurrence rate of 6.7% in the low-risk group and
of 14.7% in the high-risk group (P = 0.006). The intent-to-
treat 3-year DFS rate for patients in the high-risk group
assigned to chemotherapy or to observation was not
statistically different. When the results were analyzed based
on actual treatment delivered, however, the 3-year DFS
rate for patients treated with adjuvant chemotherapy was
9% versus 19% for patients who did not receive
chemotherapy (P = 0.016). The improvement in actuarial
3-year DFS was maintained at a median follow-up of
50 months [53].
Zemzoum and colleagues [54] showed that uPA/PAI-1
levels in primary tumor tissue are associated with an
aggressive course of disease in lymph node-negative
breast cancer, independent of HER-2 status. It has been
suggested that patients with node-negative breast cancer
and low levels of uPA and PAI-1 may be spared the trauma
of adjuvant chemotherapy [55]. However, the ELISAs of
uPA/PAI-1 require extracts of primary tumor tissue, and this
is a major limitation for patients with small tumors.
Angiogenesis-related prognostic markers
It is now accepted that solid tumors must develop a
vascular network to grow beyond 1 cm3, and they do so
by stimulating the formation of new blood vessels (so-
called angiogenesis). Angiogenesis is an active process,
regulated by a large number of pro-angiogenic and anti-
angiogenic molecules (Table 2). Interest in neovascularity
as a prognostic factor was stimulated by the work of
Folkman on tumor angiogenesis and by the potential for
treatment with anti-angiogenic agents [56].
The prognostic relevance of tumor angiogenesis in breast
cancer was first reported by Weidner and colleagues [57],
who counted microvessels (veins and arteries) in the most
densely vascularized areas of 49 invasive carcinomas and
found their number and density significantly increased in
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Table 2
Pro-angiogenic and anti-angiogenic proteins
Pro-angiogenic protein Anti-angiogenic protein
Vascular endothelial growth factor Angiostatin
Angiogenin Endostatin
Angiopoetin-1 Interferon (alpha, beta)
Del-1 Interleukin-12
Fibroblast growth factors 2-Methoxyestradiol
Follistatin Platelet factor 4
Interleukin-8 Thrombospondin
Leptin CD59 complement fragment
Placental growth factor Heparinases
Platelet-derived endothelial  Tissue inhibitors of 
growth factor metalloproteinases
Pleiotrophin Vasostatin
Transforming growth factor alpha 16-kDa prolactin fragment
Transforming growth factor beta
Tumor necrosis factor
Vascular endothelial growth factor
Hepatocyte growth factor
Nitric oxide
Erucamide
Urokinase plasminogen activator113
cases with nodal and distant metastasis. In their study, the
frequency of distant metastasis increased with an increase
in the microvessel count. However, other studies showed
conflicting results. Van Hoef and colleagues [58] reported
considerable variability in the microvessel count in different
parts of the same tumor and between the readings of two
evaluators. These investigators found no significant
correlation between microvessel count and other tumor
factors of prognostic value, and found no significant
correlation between the microvessel count and DFS. Until
these issues are resolved, microvessel count should not
be used routinely for making treatment decisions in breast
cancer patients.
Angiogenic growth factors have been identified that may
have important prognostic utility. These include the vascular
endothelial growth factor, the platelet-derived endothelial
cell growth factor (also known as thymidine phosphorylase),
and the fibroblast growth factor family [59].
Apoptosis-related prognostic markers
Programmed cell death, also know as apoptosis, is an
endogenous cellular process whereby an external signal
activates a metabolic pathway that results in cell death
(Table 3) [60]. This form of cell death is commonly seen in
breast cancer tissue. Apoptotic cells can be quantitated
by light microscopy, and an apoptotic index can be
calculated. However, the prognostic significance of the
apoptotic index is not well defined. Wu and colleagues
[61] reported a correlation between a low apoptotic index
and decreased patient survival. However, other studies
found no correlation between apoptotic index and
prognosis [62–64].
Bcl-2 is a mitochondrial protein known to inhibit apoptosis
triggered by chemotherapy and radiation therapy. Lower
levels of apoptosis could lead to malignant cell accumula-
tion and therefore to a more aggressive clinical course for
the disease. Although Bcl-2 can block apoptosis in vitro,
several studies have shown that Bcl-2 overexpression is
associated with improved DFS rates [65]. This may be in
part because of the close association between Bcl-2
expression and ER expression. Perhaps more important is
the potential association between Bcl-2 expression and
response to chemotherapy. Several studies have shown
that patients with Bcl-2-negative breast cancer were more
likely to respond to chemotherapy than patients with
Bcl-2-positive tumors [66–68]. However, other studies
found no association between Bcl-2 expression and the
response to chemotherapy [69,70]. Further studies are
needed to establish the role of Bcl-2 as a predictive factor
of response to therapy.
Genomics
In addition to the markers already discussed, literally
hundreds of other molecules have been evaluated as
potential prognostic factors. Breast cancer is a complex
heterogeneous disease, and therefore evaluation of a
handful of genes and/or proteins provides only limited
prognostic information. High-throughput gene expression
profiling using microarray technology is a promising new
technology that has been applied to the classification of
breast cancers [71–73], to prognosis [74–77], and to
prediction of response to treatment [78].
Using cDNA microarrays, Perou and colleagues [71]
classified invasive breast carcinomas into five subtypes
based on their distinct gene expression profile (Norway/
Stanford dataset). These included a luminal epithelial cell
phenotype (subtypes A and B), a basal epithelial cell type
phenotype, a HER-2 (+) phenotype, and a group of
cancers expressing a ’normal-like’ gene profile. Sorlie and
colleagues [79] showed that patients whose tumors
exhibited the basal-like and HER-2-positive subtypes had
the worst survival rates, while the luminal epithelial type
was associated with improved survival rates. Although
initially the luminal subtype correlated with ER positivity,
Sorlie and colleagues noted that the ER levels were not
uniform among tumors classified as luminal or basal types.
van’t Veer and colleagues [74] used a different microarray
platform and identified a ‘poor prognosis signature’ that
included 70 genes involved in regulation of the cell cycle,
in invasion, in metastasis, and in angiogenesis. The 70-
gene prognostic profile was validated by the same
investigators in 295 consecutive patients with primary
breast cancer [75]. Among the 295 patients, 180 had a
poor-prognosis signature and 115 had a good-prognosis
signature; the mean overall 10-year survival rates were
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Table 3
Members of the Bcl-2 family of apoptosis regulators
Inhibitor of apoptosis Promoter of apoptosis
BCL-2 BAX
BCL-XL BAK
MCL-1 BOK
A-1/BFL-1 BAD
BCL-W BID
BOO/DIVA BIK
NR-13 BLK
HRK
BIM
BNIP3
NIX
NOXA114
54.6% and 94.5%, respectively. At 10 years, the
probability of remaining free of distant metastases was
50.6% in the group with a poor-prognosis signature and
was 85.2% in the group with a good-prognosis signature.
The estimated hazard ratio for distant metastases in the
group with a poor-prognosis signature as compared with
the group with the good-prognosis signature was 5.1
(95% confidence interval, 2.9–9.0; P< 0.001). This ratio
remained significant when the groups were analyzed
according to their lymph-node status. This prognostic
signature had a strong independent value on multivariate
analysis. Ongoing studies are validating these results in
commercially available microarrays for potential clinical
and diagnostic applications.
Sorlie and colleagues [80] reanalyzed their Norway/
Stanford dataset, including 84 tissue samples from their
previously published work [71,79] and 38 additional tumor
samples from patients with locally advanced breast cancer
treated with preoperative chemotherapy. The first gene list
and the list used for the reanalyzed report had
approximately 200 genes in common, and tumors could
be classified in the five main gene clusters as previously
described. In addition, Sorlier and colleagues attempted
to validate their findings in two independent datasets
reported by Van’t Veer and colleagues [75] and by West
and colleagues [81]. Ninety-seven tumors from the van’t
Veer and colleagues’ study could be classified into the five
subtypes, and these different breast cancer types were
associated with prognosis. Patients with the luminal-A
subtype had the best survival rates, while the worst
survival rates were associated with the basal and HER-2
subtypes. However, van’t Veer and colleagues based their
analysis on 461 genes (out of 24,480). The dataset from
West and colleagues, generated on an Affymetrix
platform, could also be classified into the previously
described subtypes after selecting 242 genes out of a
total of 7129 genes.
One of the main shortcomings of microarray technology is
the lack of validation of gene sets across platforms. For
example, when Sorlie and colleagues [80] tested the
prognostic impact of the 231 markers published by van’t
Veer and colleagues on the Norwegian cohort, the
positive predictive value for DFS was only 47%. This may
in part be due to the different patient cohorts and treat-
ments. In fact, the differences in outcomes across studies
are based on the subset of genes that was analyzed in all
the studies, and the number of genes held in common
across studies is limited.
Clinical trials are evaluating the prognostic and predictive
value of gene expression profiles in patients with early-
stage breast cancer. Chang and colleagues [82] evaluated
gene expression profiles in tumors from 24 patients
undergoing neoadjuvant docetaxel chemotherapy. Core
biopsies were obtained prior to initiation of chemotherapy,
and cDNA analysis of RNA extracted from biopsy samples
was completed using the HgU95-Av2 GeneChip (Affymetrix,
Santa Clara, CA, USA). Differential patterns of expression
of 92 genes correlated with docetaxel response
(P = 0.001). Symmans and colleagues [83] showed that
fine-needle aspiration yielded sufficient RNA for gene
expression profiling. Since most breast cancer in patients
is diagnosed at an early stage, the fine-needle aspiration
approach may become acknowledged as the optimal way
to obtain tissue for gene profiling. Pusztai and colleagues
[78] extracted RNA from fine-needle aspiration specimens
and identified a group of genes that predicted pathologic
complete response to neoadjuvant chemotherapy.
Transcriptional profiling could until recently only be
completed using fresh or frozen tissue, not using tissue
from paraffin blocks. To overcome this limitation, several
groups are developing methods to extract RNA from
formalin-fixed, paraffin-embedded tissue for genomics
studies. Ma and colleagues [84] microdissected breast
cancer cells from paraffin-embedded tumors and measured
expression on more than 20,000 genes in cancer cells
using an Affymetrix platform. The authors were able to
correlate gene expression signatures with prognosis. This
is a step forward, and these findings should be validated
in groups of patients treated homogeneously or not
treated with adjuvant systemic therapy at all.
Several groups are evaluating the prognostic and
predictive value of a multigene RT-PCR assay using
paraffin-embedded tissue (Oncotype DX™; Genomic
Health, Redwood City, CA, USA). Sixteen genes had
significant prognostic value in three preliminary studies
that included patients with early-stage breast cancer
treated with adjuvant tamoxifen and/or chemotherapy
[85–87]. Five genes were added as reference genes, and
a recurrence score was developed. Paik and colleagues
[85] showed that the multigene RT-PCR assay had a
strong predictive value in patients with a history of node-
negative, ER-positive tumors treated with tamoxifen in the
adjuvant setting. The 10-year distant recurrence rate was
6.8% for patients with a low recurrence score, was 14.3%
for patients with an intermediate recurrence score, and
was 30.5% for patients with a high recurrence score.
A smaller study conducted at MD Anderson Cancer
Center showed no relationship between OncotypeDX’s
recurrence score and distant recurrence-free survival in
patients with node-negative breast cancer who had not
received any adjuvant systemic therapy [88]. Although
there may be many explanations for this finding, it is also
possible that the model is good at predicting response or
lack of response to tamoxifen but has limited prognostic
power. More studies are needed to establish the
prognostic role of this assay in clinical management.
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Proteomics
In the postgenome era, scientists have turned to proteomics
to understand complex biological systems. Proteomics is
defined as the identification, characterization, and
quantification of all proteins involved in a particular tissue,
organ, or organism to provide accurate and compre-
hensive data about that system.
One of the methods most commonly used to study
differences in protein expression between two samples
(e.g. cancer and normal tissue) is two-dimensional gel
electrophoresis. Highly sensitive mass spectrometry
methods are currently being used together to identify
greater numbers of lower abundance proteins that are
differentially expressed in defined cell populations. Matrix-
assisted laser desorption/ionization time-of-flight and
surface-enhanced laser desorption/ionization time-of-flight
analyses enable high-throughput characterization of
lysates from even a very few tumor cells, and they may be
best suited for clinical biomarker studies [89,90].
Novel technologies still in developmental phases will enable
identification of validated targets in small biopsy specimens,
including high-density protein, antibody, and lysate arrays
[91,92]. No proteomics-based assay for assessing
prognosis in breast cancer patients has yet been developed.
Conclusion
Prognostic and predictive molecular markers commonly
used in clinical practice include Ki-67, ER, PR, and HER-2.
From the National Institute of Health overview it was clear
that, once basic pathology had been excluded, there was
very little else that had been appropriately validated and in
which there was good quality control. This issue of quality
control is one of the most important challenges for
validation of most molecular markers discussed.
Prognostic indices that integrate clinical, histologic, and
molecular parameters will need to be developed and
validated in conjunction with novel bioinformatic methodol-
ogies (i.e. artificial intelligence) to aid clinical decision-
making. High-throughput cDNA microarray technologies
and tumor array technologies are allowing the expression
of literally thousands of genes and proteins to be analyzed
at one time. Validation of these technologies in adequately
powered prospective clinical trials will allow the integration
of multiple molecular factors in the risk assessment and
management of individual patients with breast cancer.
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